

August 22, 2023

**To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001**

**To,  
The Manager – Listing,  
The National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051**

**Ref: Scrip Code: 532296**

**Ref: Scrip Name: GLENMARK**

Dear Sir,

**Sub: Press Release of our wholly owned subsidiary company relating to Antitrust settlement with DOJ**

Please find enclosed herewith a Press Release issued by our wholly owned subsidiary company Glenmark Pharmaceuticals Inc., USA relating to entering into an agreement with U.S. Department of Justice, Antitrust Division (DOJ).

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

**Harish Kuber  
Company Secretary & Compliance Officer**

**Encl: as above**

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)

Press Release

For Immediate Release

## **Glenmark Pharmaceuticals Inc., USA Reaches Antitrust Settlement with DOJ**

**Mahwah, New Jersey; August 22, 2023:** Glenmark Pharmaceuticals Inc., USA (“Company”) announced today that it has entered into an agreement with the U.S. Department of Justice, Antitrust Division (DOJ) to resolve all of its court proceedings with the DOJ involving historical pricing practices by former employees relating to the generic drug pravastatin between 2013 and 2015. The Company has entered into a three-year Deferred Prosecution Agreement, and if the Company adheres to the terms of the agreement, including the payment of \$30 million, payable in six installments, the DOJ will dismiss the pending Superseding Indictment.

*“Glenmark is committed to being a socially and ethically responsible company. We have devoted considerable resources to strengthen our compliance practices, ensuring the highest ethical operating standards. We will continue to conduct our business with the utmost transparency and integrity,” said Sanjeev Krishan, President, Glenmark Pharmaceuticals Inc., USA.*

---End---

### **About Glenmark Pharmaceuticals Inc., USA**

Glenmark Pharmaceuticals Inc., USA (GPI) is a wholly-owned subsidiary of Glenmark Holding SA. GPI is an innovation-driven pharmaceutical company with a significant presence in the generic product segment in the United States; with a focus on therapeutic areas of respiratory, dermatology, and oncology. For more information, visit [www.glenmarkpharma-us.com](http://www.glenmarkpharma-us.com).

### **For further information, please contact:**

Danielle Hagen | [glenmark@nahigianstrategies.com](mailto:glenmark@nahigianstrategies.com)